Cingulate Inc (CING)

$3.86 +0.28 (7.82%)
Market Cap 19.38M
Revenue (ttm) 0.00
Net Income (ttm) -15.55M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 371,200
Avg Vol 177,604
Day's Range N/A - N/A
Shares Out 5.41M
Stochastic %K 36%
Beta -0.75
Analysts Strong Sell
Price Target $30.40

Company Profile

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1...

Industry: Biotechnology
Sector: Healthcare
Phone: 913 942 2300
Address:
1901 West 47th Place, Kansas City, United States
ZacksResearch
ZacksResearch Oct. 24 at 8:50 PM
$CING gets a big spotlight at AACAP šŸŽÆ Cingulateā€™s lead ADHD candidate, CTx-1301, was selected for a podium presentation at the American Academy of Child and Adolescent Psychiatry Annual Meeting ā€” a strong validation of its Phase 3 data and scientific rigor. šŸ’Š The once-daily, extended-release design aims to simplify ADHD treatment and address key limitations of current stimulant therapies. See what Wall Street expects next šŸ‘‰ https://www.zacks.com/stock/research/CING/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-17687&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_17687
0 Ā· Reply
lordofthesox
lordofthesox Oct. 24 at 7:03 PM
$CING I expect a lot of this up and down but no real movement until we get a real catalyst.
1 Ā· Reply
PhiloftheFuture
PhiloftheFuture Oct. 24 at 6:15 PM
Loaded up on my highest conviction holdings over the past week. $CRSP $RDW $CADL $CING
0 Ā· Reply
Itinerant
Itinerant Oct. 24 at 2:23 PM
$CING This company is seriously under valued. I have established my initial long position. JMO
1 Ā· Reply
fullobullz
fullobullz Oct. 24 at 1:15 PM
$CING Ctx1301 presentation today by Dr Ann
1 Ā· Reply
Hrk024
Hrk024 Oct. 24 at 1:10 AM
$CING šŸ§ØšŸ§ØšŸ§ØšŸš€šŸš€šŸš€šŸš€šŸš€šŸ˜ŽšŸ‘Œ
0 Ā· Reply
ru8fru
ru8fru Oct. 23 at 9:25 PM
$CING added
0 Ā· Reply
unearthedmosquito
unearthedmosquito Oct. 23 at 9:23 PM
$CING Adding 3.70s, ahead of CTx-1301 data
0 Ā· Reply
pitkineagle
pitkineagle Oct. 23 at 9:10 PM
$CING Dr. Ann šŸ’ŖšŸ»šŸ’ŖšŸ»šŸ’ŖšŸ»
0 Ā· Reply
STKH
STKH Oct. 23 at 8:53 PM
$CING Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
0 Ā· Reply
Latest News on CING
Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Oct 23, 2025, 4:45 PM EDT - 1 day ago

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

Sep 17, 2025, 8:45 AM EDT - 5 weeks ago

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25

Aug 21, 2025, 4:35 PM EDT - 2 months ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25

Cingulate Inc. Reports Second Quarter 2025 Financial ResultsĀ and Provides Recent Highlights

Aug 19, 2025, 8:45 AM EDT - 2 months ago

Cingulate Inc. Reports Second Quarter 2025 Financial ResultsĀ and Provides Recent Highlights

Cingulate Provides Management Team Update

Aug 15, 2025, 9:00 AM EDT - 2 months ago

Cingulate Provides Management Team Update

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Aug 6, 2025, 8:45 AM EDT - 2 months ago

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)

Jun 18, 2025, 8:00 AM EDT - 4 months ago

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

May 8, 2025, 4:30 PM EDT - 6 months ago

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Apr 9, 2025, 8:00 AM EDT - 7 months ago

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results,Ā and Provides Development Update on Major Milestones Achieved

Mar 26, 2025, 5:00 PM EDT - 7 months ago

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results,Ā and Provides Development Update on Major Milestones Achieved

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Dec 23, 2024, 7:30 AM EST - 10 months ago

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Cingulate Reports Third Quarter 2024 Financial ResultsĀ Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Nov 7, 2024, 7:30 AM EST - 1 year ago

Cingulate Reports Third Quarter 2024 Financial ResultsĀ Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Oct 8, 2024, 3:15 PM EDT - 1 year ago

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Sep 12, 2024, 8:30 AM EDT - 1 year ago

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Cingulate to Participate in Benzinga All Live Access Event

Aug 27, 2024, 4:30 PM EDT - 1 year ago

Cingulate to Participate in Benzinga All Live Access Event

Cingulate Announces Adjournment of Special Meeting

Aug 23, 2024, 4:45 PM EDT - 1 year ago

Cingulate Announces Adjournment of Special Meeting

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Aug 16, 2024, 12:36 PM EDT - 1 year ago

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Aug 15, 2024, 7:45 AM EDT - 1 year ago

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Cingulate Reports Second Quarter 2024 Financial ResultsĀ and Provides Development Update on Major Milestones Achieved

Aug 13, 2024, 7:45 AM EDT - 1 year ago

Cingulate Reports Second Quarter 2024 Financial ResultsĀ and Provides Development Update on Major Milestones Achieved

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Jun 28, 2024, 9:15 AM EDT - 1 year ago

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Jun 25, 2024, 4:30 PM EDT - 1 year ago

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

Jun 25, 2024, 9:20 AM EDT - 1 year ago

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

Cingulate Reports First Quarter 2024 Financial ResultsĀ and Provides Clinical and Business Update

May 8, 2024, 7:00 AM EDT - 1 year ago

Cingulate Reports First Quarter 2024 Financial ResultsĀ and Provides Clinical and Business Update

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Apr 30, 2024, 5:45 AM EDT - 1 year ago

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Apr 16, 2024, 5:00 PM EDT - 1 year ago

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial ResultsĀ and Provides Clinical and Business Update

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial ResultsĀ and Provides Clinical and Business Update

Cingulate to Attend DCAT Week 2024 in New York City

Mar 6, 2024, 6:45 AM EST - 1 year ago

Cingulate to Attend DCAT Week 2024 in New York City

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Feb 13, 2024, 6:45 AM EST - 1 year ago

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Cingulate Announces Closing of $7.5 Million Public Offering

Feb 6, 2024, 4:15 PM EST - 1 year ago

Cingulate Announces Closing of $7.5 Million Public Offering

Cingulate Announces Pricing of $7.5 Million Public Offering

Feb 2, 2024, 9:15 AM EST - 1 year ago

Cingulate Announces Pricing of $7.5 Million Public Offering

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Jan 29, 2024, 8:00 AM EST - 1 year ago

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Jan 29, 2024, 6:45 AM EST - 1 year ago

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Dec 28, 2023, 7:19 AM EST - 1 year ago

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Dec 1, 2023, 9:00 AM EST - 2 years ago

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Cingulate Inc. Reports Third Quarter 2023 Financial ResultsĀ and Provides Clinical and Business Update

Nov 13, 2023, 4:15 PM EST - 2 years ago

Cingulate Inc. Reports Third Quarter 2023 Financial ResultsĀ and Provides Clinical and Business Update

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Oct 17, 2023, 2:22 PM EDT - 2 years ago

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Cingulate Inc. to Present at the LD Micro Main Event XVI

Sep 21, 2023, 1:30 PM EDT - 2 years ago

Cingulate Inc. to Present at the LD Micro Main Event XVI

Cingulate Inc. To Present at the LD Micro Main Event XVI

Sep 21, 2023, 11:23 AM EDT - 2 years ago

Cingulate Inc. To Present at the LD Micro Main Event XVI

Cingulate Announces Closing of $4.0 Million Public Offering

Sep 13, 2023, 4:15 PM EDT - 2 years ago

Cingulate Announces Closing of $4.0 Million Public Offering

Cingulate Announces Pricing of $4.0 Million Public Offering

Sep 11, 2023, 9:22 AM EDT - 2 years ago

Cingulate Announces Pricing of $4.0 Million Public Offering

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Sep 11, 2023, 6:00 AM EDT - 2 years ago

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Sep 8, 2023, 4:31 PM EDT - 2 years ago

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics' CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

Sep 6, 2023, 9:00 AM EDT - 2 years ago

Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics' CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

Cingulate Inc. Reports Second Quarter 2023 Financial ResultsĀ and Provides Clinical and Business Update

Aug 14, 2023, 4:15 PM EDT - 2 years ago

Cingulate Inc. Reports Second Quarter 2023 Financial ResultsĀ and Provides Clinical and Business Update

Cingulate Successfully Manufactures Clinical Supply ā€“ Initiation of Pediatric Phase 3 Studies to Commence in July and August

Jun 29, 2023, 8:00 AM EDT - 2 years ago

Cingulate Successfully Manufactures Clinical Supply ā€“ Initiation of Pediatric Phase 3 Studies to Commence in July and August

Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest

Jun 14, 2023, 3:45 PM EDT - 2 years ago

Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest

Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD

Jun 8, 2023, 7:00 AM EDT - 2 years ago

Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD

Cingulate to Present at 13th Annual LD Micro Invitational

May 25, 2023, 3:55 PM EDT - 2 years ago

Cingulate to Present at 13th Annual LD Micro Invitational

Cingulate, Indegene to Participate in Benzinga All Live Access Event

May 12, 2023, 3:45 PM EDT - 2 years ago

Cingulate, Indegene to Participate in Benzinga All Live Access Event

ZacksResearch
ZacksResearch Oct. 24 at 8:50 PM
$CING gets a big spotlight at AACAP šŸŽÆ Cingulateā€™s lead ADHD candidate, CTx-1301, was selected for a podium presentation at the American Academy of Child and Adolescent Psychiatry Annual Meeting ā€” a strong validation of its Phase 3 data and scientific rigor. šŸ’Š The once-daily, extended-release design aims to simplify ADHD treatment and address key limitations of current stimulant therapies. See what Wall Street expects next šŸ‘‰ https://www.zacks.com/stock/research/CING/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-17687&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_17687
0 Ā· Reply
lordofthesox
lordofthesox Oct. 24 at 7:03 PM
$CING I expect a lot of this up and down but no real movement until we get a real catalyst.
1 Ā· Reply
PhiloftheFuture
PhiloftheFuture Oct. 24 at 6:15 PM
Loaded up on my highest conviction holdings over the past week. $CRSP $RDW $CADL $CING
0 Ā· Reply
Itinerant
Itinerant Oct. 24 at 2:23 PM
$CING This company is seriously under valued. I have established my initial long position. JMO
1 Ā· Reply
fullobullz
fullobullz Oct. 24 at 1:15 PM
$CING Ctx1301 presentation today by Dr Ann
1 Ā· Reply
Hrk024
Hrk024 Oct. 24 at 1:10 AM
$CING šŸ§ØšŸ§ØšŸ§ØšŸš€šŸš€šŸš€šŸš€šŸš€šŸ˜ŽšŸ‘Œ
0 Ā· Reply
ru8fru
ru8fru Oct. 23 at 9:25 PM
$CING added
0 Ā· Reply
unearthedmosquito
unearthedmosquito Oct. 23 at 9:23 PM
$CING Adding 3.70s, ahead of CTx-1301 data
0 Ā· Reply
pitkineagle
pitkineagle Oct. 23 at 9:10 PM
$CING Dr. Ann šŸ’ŖšŸ»šŸ’ŖšŸ»šŸ’ŖšŸ»
0 Ā· Reply
STKH
STKH Oct. 23 at 8:53 PM
$CING Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
0 Ā· Reply
TA_Kongen
TA_Kongen Oct. 23 at 8:47 PM
$CING There is no way this is NOT gonna end up a dud.
3 Ā· Reply
Mprifold
Mprifold Oct. 23 at 4:46 PM
$CING like I said 3.50 incoming. Wait until after earnings to jump in around 3.30-3.00 range.
1 Ā· Reply
aak12345
aak12345 Oct. 23 at 3:35 PM
$CING started a position here
0 Ā· Reply
Irakli2508
Irakli2508 Oct. 23 at 3:23 PM
$CING I added 1200 shares today.
0 Ā· Reply
Irakli2508
Irakli2508 Oct. 23 at 2:54 PM
$CING
0 Ā· Reply
SamMusaX
SamMusaX Oct. 23 at 12:58 AM
$CING Each week we get closer to Office Action. In the 16 week window we are entering week 4. There are only 12 weeks left before we see office action at a the latest! Based on historical averages for pharmaceutical filings, the First Office Action is anticipated between Oct 2025 - Jan 2026.
2 Ā· Reply
SamMusaX
SamMusaX Oct. 23 at 12:57 AM
$CING The Wednesday Weekly USA patent update. Change or no change, every Wednesday, will be posting it: Hereā€™s the updated status for Application US 18/661,378 (Tripulse Release Stimulant Formulations), as of October 22, 2025: ________________________________________ Application US18/661,378 (Tripulse Release Stimulant Formulations) ā€¢ 2024-05-10 ā€“ Application filed by Cingulate Therapeutics LLC ā€¢ 2024-05-10 ā€“ Priority date established (same day as filing) ā€¢ 2024-11-11 ā€“ Assignment recorded to Cingulate Therapeutics LLC (Reel/Frame 069201/0426) ā€¢ 2025-02-13 ā€“ Publication of application as US 2025/0049722 A1 ā€¢ 2025-10-22 (today) ā€“ Status: Pending (no Office Action issued yet; still early in prosecution) ________________________________________ Notes ā€¢ The application remains in the early USPTO examination phase. ā€¢ No new docket updates, examiner assignment, or correspondence have appeared since publication. ā€¢ the First Office Action is still projected for late-2025 to Q1 2026.
0 Ā· Reply
StockGuru320
StockGuru320 Oct. 22 at 12:13 PM
$BBAI I loaded the fucking boat this morning! See short interest! This is gonna take off like a rocket IMO! Loaded $BBAI and $CING heavily.
0 Ā· Reply
StockGuru320
StockGuru320 Oct. 21 at 5:51 PM
$CING @Ro_Patel
1 Ā· Reply
StockGuru320
StockGuru320 Oct. 21 at 5:50 PM
$CING The myth, the man, the legendā€¦ AKA the KING of ADHD LFGā€¦this team is stacked.
0 Ā· Reply
StockGuru320
StockGuru320 Oct. 21 at 1:56 PM
$CING buying more!
0 Ā· Reply
activehybrid
activehybrid Oct. 20 at 8:02 PM
$CING updated presentation is available in http://Cingulate.com $200 million is targeted
0 Ā· Reply